著者
石丸 博雅 津田 泰正 景 秀典 河野 友昭 高山 慎司 森元 能仁 後藤 一美 渡部 一宏
出版者
公益社団法人 日本薬学会
雑誌
YAKUGAKU ZASSHI (ISSN:00316903)
巻号頁・発行日
vol.141, no.1, pp.143-150, 2021-01-01 (Released:2021-01-01)
参考文献数
28
被引用文献数
1

Occupational exposure to anticancer drugs may increase the risk of cancer and the risk of miscarriage and stillbirth, and cause other adverse events such as hypersensitivity reactions, skin/mucous reactions, and digestive symptoms. Several studies have investigated the use of closed-system drug-transfer devices (CSTDs) to reduce the environmental pollution by hazardous drugs. However, few reports have verified whether CSTDs contain the hazardous drugs within the vials. The BD PhaSealTM System is a CSTD that is frequently used in Japan. However, the fit of each anti-cancer drug vial has not been investigated. We investigated the fit of 71 major anti-cancer drug vials and protectors released and frequently used in Japan by means of a pressure compatibility test that we developed. The pressure compatibility test involved attaching a three-way stopcock to a Luer lock syringe and attaching an injector in line with the syringe. The pressure tubing was connected to the other side of the three-way stopcock and connected to the pressure inlet of the pressure gauge. The pressure in the anti-cancer drug vial was raised to 100 kPa and connected/disconnected repeatedly. If the pressure fluctuation during the 10th connection was within 6%, it was defined as “no change”, and the compatibility of the protector and the vial was evaluated. The median pressure reduction rates at the 10th connection ranged from −1.98% to −4.95%. All drugs surveyed had an error rate within 6%. The BD PhaSealTM Protector was shown to be compatible with the 71 anti-cancer drugs we surveyed.
著者
後藤 一美 丸山 友裕
出版者
医学書院
雑誌
臨床皮膚科 (ISSN:00214973)
巻号頁・発行日
vol.57, no.12, pp.1131-1133, 2003-11-01

掌蹠・腋窩多汗症患者10例に対して,入院の上,水道水イオントフォレーシスを行った.治療期間は約2週間,治療時間は各10~20分,1日1~3回連日施行した.効果判定は患者の自己評価に基づいて行った.手掌では,10例中著効6例,有効2例,やや有効2例,足底では,7例中著効1例,有効4例,やや有効2例,腋窩では,3例中著効2例,やや有効1例であった.また,各部位の全対象患者において無効例は認められず,本療法の有用性が示唆された.